The Effect of Midazolam Sedation on Diagnostic Medial Branch Blocks

NCT ID: NCT04453449

Last Updated: 2022-03-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

95 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-25

Study Completion Date

2021-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective observational study aims to investigate the effect of midazolam sedation on the diagnostic validity of diagnostic lumbar medial branch block in patients diagnosed with lumbar spondylosis without myelopathy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective observational study aims to investigate the effects of midazolam sedation on the diagnostic validity of lumbar medial branch blocks in patients diagnosed with lumbar spondylosis without myelopathy. Patients typically receive two subsequent diagnostic blocks prior RFTC, to ensure that the correct location has been targeted. When patients achieve at least 80% pain relief after both diagnostic blocks, this is considered a positive result and they can proceed to receive RFTC. If patients have positive diagnostic blocks but their RFTC is not successful, this is considered a false positive diagnostic result. This study will determine 1) if a higher number of sedated patients proceed to radiofrequency thermocoagulation (RFTC) than non-sedated patients, and 2) if there are a higher number of false positive results in sedated patients. The hypothesis is that the use of midazolam sedation will increase the number of patients who perceive to have pain relief from their diagnostic block results, resulting in more patients proceeding to RFTC, and that there will be a higher number of false positive results in sedated patients. The primary outcome measure is the number of sedated versus non-sedated patients that have positive block results. A positive result will be calculated by having at least one NRS score that is at least 80% lower than their baseline NRS score in the 8 hours following lumbar MBB. The secondary outcome will be the number of false positive blocks in sedated versus non-sedated patients. After patients achieve 80% relief after each of the two diagnostic lumbar medial branch blocks and proceeds with lumbar RFTC, we will then collect NRS scores 24 hours after both diagnostic Lumbar MBB, and 4 weeks and at 8 weeks after the lumbar RFTC. If a patient has not received at least 50% reduction from their baseline NRS score by 8 weeks, this will be considered a false positive. A 7-point Patient Global Impression of Change (PGIC) score 8 hours after each Lumbar MBB will also be collected, and at 4 weeks and 8 weeks after the lumbar RFTC, and any adverse effects patients experience. In addition, Oswestry Disability Index (ODI) will be collected at 4 and 8 weeks after lumbar RFTC. The results of this study will help guide the use of sedation when performing diagnostic blocks on patients with lumbar spondylosis, in order to reduce the number of false positive blocks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lumbar Spine Spondylosis Anxiety Generalized

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No sedation

Patients who will undergo the diagnostic lumbar medial branch blocks without sedation (control group).

No interventions assigned to this group

Sedation

Patients who will undergo the diagnostic lumbar medial branch blocks with midazolam sedation (treatment group).

Midazolam

Intervention Type DRUG

Midazolam given as a sedative during diagnostic lumbar medial branch block

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Midazolam

Midazolam given as a sedative during diagnostic lumbar medial branch block

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

sedation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients at least 18 years of age
* History of axial low back pain for at least 3 months
* Indication for bilateral lumbar medial branch block (L3, L4, L5 medial branch nerves)
* Diagnosis of Lumbar Spondylosis without Myelopathy \>4/10 pain on a 0-10 numerical rating scale (NRS)

Exclusion Criteria

* Low back pain with radiculopathy symptoms (this is a diagnosis of sciatica and treatment is not with lumbar medial branch block)
* Uncontrolled major depression or other mental health issues causing instability
* Pregnant or lactating women
* \<18 years old
* History of adverse reaction to either midazolam, lidocaine, or bupivacaine
* Focal neurological deficits, cognitive impairments, or memory issues
* Non-English speaking
* Hearing impaired that are unable to understand verbal instructions
* Active Infection
* On Anticoagulation or Antiplatelet Therapy
* History of Clotting Disorder
* Previous Lumbar Medial Branch Block and/or Lumbar Radiofrequency Ablation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Henry Ford Health System

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Katherine Nowak

Research Manager

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Henry Ford Health System

Detroit, Michigan, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Patel N, Nowak K, Vaidyanathan A, Milad H, Adlaka K, Rubino C, Vasquez ET, Nerusu L, Rahavard B, Fayed M, Forrest P, Money S, Dwivedi S, Zador L, Haddad R, Khaja D, Sibai N, Aiyer R. The Effect of Sedation on Diagnostic Lumbar Medial Branch Blocks for Facetogenic Low Back Pain: An Observational Study. Pain Physician. 2024 May;27(4):E407-E418.

Reference Type DERIVED
PMID: 38805536 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

14010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sedation During Spinal Anesthesia
NCT03133780 COMPLETED PHASE2